Finally, therapy with navitoclax, in combination with the thymidylate synthase inhibitors raltitrexed or the clinically prevalent drug capecitabine, caused marked and prolonged tumor regression in prostate and breast cancer xenograft models. This evidence concerns the gene TYMS and neoplasm.